We provide total solutions that enhance the value of life.
Biosimilar Research
Biosimilars are products that have equivalent efficacy and safety to previously approved reference biologics. They can be developed at lower cost through streamlined regulatory pathways, providing an alternative therapeutic option that improves patient access to innovative treatments.
Daewoong Pharmaceutical is building a diverse biosimilar pipeline by leveraging its in-house development capabilities and global partnerships. This enables patients to receive high-quality biopharmaceuticals reliably at affordable costs, thereby contributing to the realization of global medical equity.
Going beyond biosimilars, Daewoong Pharmaceutical is expanding its capabilities across the broader biopharmaceutical sector to advance toward becoming a global biopharma leader. The company is accelerating development with the goal of launching 10 biosimilar products by 2030.
Core Competency
As a specialized biopharmaceutical company, Daewoong Pharmaceutical is committed to leading innovation and expanding its portfolio to improve global patient access to high-quality therapies. In particular, the company focuses on building a diverse biosimilar pipeline across key therapeutic areas, including oncology, immunology and inflammation, dermatology, and respiratory diseases.
Daewoong Pharmaceutical’s biosimilar portfolio spans a wide range of products, from blockbuster biologics to therapies tailored for specific patient populations. This reflects its commitment to expanding treatment opportunities for more patients. Through this development strategy, the company aims to make advanced biopharmaceuticals more accessible at a reasonable cost across a broader range of countries and regions, thereby contributing to the realization of global medical equity.
Core Competency
Defining new paradigms in treatment through advanced technology and differentiated research
Core Competency 01
Highly Skilled Talent with Integrated Expertise and Experience
Daewoong Pharmaceutical’s biosimilar organization brings together experts from diverse fields through its global network, enabling collaboration across the entire development process. By integrating strong scientific capabilities with proven industry experience, the company executes all projects with precision and rigor, ensuring high-quality development capability.
Core Competency 02
Cost Efficiency with High Quality
Based on innovative development strategies and proprietary know-how, Daewoong Pharmaceutical maximizes development cost efficiency. At the same time, it maintains rigorous global quality standards, enabling more patients to access high-quality biopharmaceuticals at a reasonable cost.
Core Competency 03
Fast and Flexible Development
With a deep understanding of the rapidly evolving global regulatory environment, Daewoong Pharmaceutical has established an efficient clinical development speed and a flexible operating model. This enables the company to effectively shorten development timelines, respond swiftly to partner and market needs, and secure a competitive advantage.
Business Strategy & Partnering
Daewoong Pharmaceutical’s biosimilar business strategy is based on a multifaceted approach to strengthening its position in both domestic and global markets. The company secures biosimilar products through a global license-in strategy and pursues co-development partnerships with other biosimilar companies to share expertise and resources. Through these efforts, Daewoong Pharmaceutical efficiently manages development costs and timelines, accelerates entry into global markets, and expands treatment opportunities for more patients.
At the same time, the company is actively investing in its end-to-end in-house development capabilities to enhance independence and strengthen long-term competitiveness in the biosimilar field.
“To achieve these strategic goals, we are actively exploring diverse collaboration opportunities in the biosimilar space.”
In addition, Daewoong Pharmaceutical aims to advance beyond biosimilars into the development of biobetters. By leveraging its proprietary high-concentration formulation technology, the company seeks to provide next-generation subcutaneous injection therapies with improved efficacy, safety, and patient convenience.
OPEN COLLABORATION
Cost-sharing and profit-sharing model
Direct commercialization in selected regions of the global market (including Korea)
Maximizing sales of in-licensed products through established sales networks
Korea and Southeast Asian markets
(including Indonesia, the Philippines, Thailand)
Daewoong Pharmaceutical is actively pursuing co-development and licensing partnerships as part of its strategic expansion into global markets. By sharing expertise and core resources with global partners, the company reduces development costs, improves timeline efficiency, and minimizes project risks through an advanced development model.
In collaboration with global partners, Daewoong Pharmaceutical is developing pipelines that meet global standards and establishing market strategies that reflect regulatory requirements in key advanced markets such as the United States and Europe. In addition, the company leverages its sales networks in Korea and Southeast Asia to maximize the commercial value of co-developed and in-licensed products.
Through these global partnership strategies, Daewoong Pharmaceutical is building a framework for sustainable growth and innovation together with partners worldwide. The company welcomes collaboration with organizations seeking to strengthen their competitiveness in global markets.